Video library​

Explore videos featuring leading oncologists offering their expert insights on key topics related to TEVIMBRA, including clinical data from phase 3 trials, product design, dosing, and access.

Overall Survival Data and the National Comprehensive Cancer Network® (NCCN®) Recommendations

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the inclusion of tislelizumab-jsgr (TEVIMBRA) in the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1L ESCC and 1L GC/GEJC and examines overall survival data for patients treated with tislelizumab-jsgr (TEVIMBRA®) + chemotherapy vs placebo + chemotherapy.

Navigating Formulary Access to TEVIMBRA

Dani Castillo, MD, discusses the process for obtaining formulary approval for TEVIMBRA in her practice.

Dosing Flexibility with TEVIMBRA

Ronan J. Kelly, MD, MBA, reviews dosing with TEVIMBRA, including its flexible regimen options across its approved indications.1

PD-L1 Testing (TAP vs CPS)

Ronan J. Kelly, MD, MBA, explains TAP, the PD-L1 scoring method used in the clinical trials of TEVIMBRA.

RATIONALE-305 OS Subgroup Analyses

Dr. Dani Castillo, MD, reviews subgroup analyses of overall survival, which included positive overall survival with TEVIMBRA + chemotherapy in patients with peritoneal metastases.2

RATIONALE-305 Study Design

Dr. Ronan J. Kelly, MD, MBA, reviews RATIONALE-305, a phase 3 trial that evaluated efficacy and safety outcomes with TEVIMBRA + chemotherapy in patients with 1L, unresectable or metastatic, HER2-negative GC or GEJC.

RATIONALE-306 Study Design

Dr. Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, reviews RATIONALE-306, a phase 3 trial that evaluated efficacy and safety outcomes with TEVIMBRA + chemotherapy in patients with 1L, unresectable, advanced or metastatic ESCC.

TEVIMBRA Mechanism of Action

Ronan J. Kelly, MD, MBA, discusses how TEVIMBRA is a unique PD-1 inhibitor.
Explore patient support
from myBeOneSupport®

1L, first line; CPS, combined positive score; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death ligand 1; TAP, tumor area positivity.

Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026. 

You are being redirected to nccn.org

Continue
Cancel
This site is intended for US healthcare professionals only. Please confirm you are a US healthcare professional.
test
Visit the patient site

You are being redirected to myBeOneSupport.com

Continue
Cancel